From GlobeNewswire: 2024-05-13 08:00:00

Compass Therapeutics received FDA Fast Track Designation for CTX-009 in combination with paclitaxel for biliary tract tumors. Enrollment in COMPANION-002 and COMPANION-003 studies is progressing well. They plan to complete enrollment by mid-2024 with top-line data expected in 2025. The company also dosed the first patient in a first-in-human clinical study for Advanced CTX-8371.

In a business update, Compass Therapeutics reported a net loss of $10.8 million for the quarter ended March 31, 2024. Research and Development expenses increased due to clinical costs related to CTX-009. Cash and marketable securities were $156.3 million as of March 31, 2024, extending the cash runway into late 2026. The company is focusing on developing novel product candidates to target critical biological pathways for an effective anti-tumor response.



Read more at GlobeNewswire:: Compass Therapeutics Reports 2024 First Quarter Financial